Last reviewed · How we verify
Y-2 sublingual tablets
Y-2 sublingual tablets is a Small molecule drug developed by Peking University Third Hospital. It is currently in Phase 3 development for Treatment of acute ischemic stroke.
Y-2 sublingual tablets' mechanism is not well-documented.
Y-2 sublingual tablets are a small molecule intervention being studied in clinical trials for various conditions, including stroke and intracranial hemorrhages. The primary purpose of these trials is to evaluate the pharmacokinetics, safety, and tolerability of Y-2 sublingual tablets in healthy adult subjects and potentially in patients with stroke and intracranial hemorrhages.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Y-2 sublingual tablets |
|---|---|
| Sponsor | Peking University Third Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on the exact mechanism of action of Y-2 sublingual tablets.
Approved indications
- Treatment of acute ischemic stroke
Common side effects
- Hypotension
- Headache
- Dizziness
Key clinical trials
- A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects (PHASE1)
- Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke (PHASE3)
- Safety, Tolerability and Pharmacokinetics of Y-2(Edaravone And Borneol) Sublingual Tablet (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Y-2 sublingual tablets CI brief — competitive landscape report
- Y-2 sublingual tablets updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI
Frequently asked questions about Y-2 sublingual tablets
What is Y-2 sublingual tablets?
How does Y-2 sublingual tablets work?
What is Y-2 sublingual tablets used for?
Who makes Y-2 sublingual tablets?
What development phase is Y-2 sublingual tablets in?
What are the side effects of Y-2 sublingual tablets?
Related
- Manufacturer: Peking University Third Hospital — full pipeline
- Indication: Drugs for Treatment of acute ischemic stroke
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing